Figure 3.
Patients with TKI-PFS less than 10 months had better response to immunotherapy than those with longer TKI-PFS. (A) Patients with TKI-PFS less than 10 months had significantly prolonged PFS than those with longer TKI-PFS; (B) Patients with TKI-PFS less than 10 months had significantly higher ORR to immunotherapy than those with longer TKI-PFS; (C) Forest plot of subgroup analysis by baseline characteristics for IO-PFS in patients with short or long TKI-PFS. *p < 0.05.